{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:16:47Z","timestamp":1778401007235,"version":"3.51.4"},"reference-count":126,"publisher":"Informa UK Limited","issue":"9","funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologics SA funded all costs associated with the development and publishing of the manuscript","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2018,9,2]]},"DOI":"10.1080\/14760584.2018.1516551","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T04:24:38Z","timestamp":1536207878000},"page":"797-818","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience"],"prefix":"10.1080","volume":"17","author":[{"given":"Tomas","family":"Mrkvan","sequence":"first","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen I.","family":"Pelton","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ruiz-Gui\u00f1az\u00fa","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arto A.","family":"Palmu","sequence":"additional","affiliation":[{"name":",","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Borys","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"e_1_3_6_3_1","first-page":"129","article-title":"Pneumococcal vaccines. WHO position paper - 2012","volume":"87","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. Pneumococcal vaccines. WHO position paper - 2012. Wkly Epidemiol Rec. 2012;87:129\u2013144.","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.113"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318199f8ef"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182323ac2"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1164044"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1333905"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.006"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-015-0483-8"},{"key":"e_1_3_6_11_1","unstructured":"Almeida SC Cassiolato AP Amorim CS et al. Increase in 19A and 6C serotypes after 5 years of PCV10 routine immunization in Brazil. 10th International Symposium on Pneumococci and Pnemococcal Diseases; 2016 Jun 26-30; Glasgow UK."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61854-6"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piw010"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001657"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085459"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.086"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis922"},{"key":"e_1_3_6_18_1","volume-title":"SIREVA II regional reports [internet]","author":"Pan American Health Organization","year":"2012","unstructured":"Pan American Health Organization. SIREVA II regional reports [internet]. Washington (DC): PAHO; 2012 [cited 2017 Nov 29]. Available from: http:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=5536&Itemid=3966&lang=en"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0034-8910.2015049006058"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120290"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.03.001"},{"key":"e_1_3_6_22_1","unstructured":"Rinta-Kokko H Auranen K Palmu A et al. Effectiveness of 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) during ongoing national vaccination programme (NVP) in Finland. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India."},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015080"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3033-5"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70060-8"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.007"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1117713"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166736"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.010"},{"key":"e_1_3_6_30_1","unstructured":"Erlendsd\u00f3ttir H Haraldsson A Hrafnkelsson B et al. An early reduction of invasive pneumococcal infections after PCV-10 immunisation. Poster session presented at: 9th International Symposium on Pneumococci and Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India."},{"key":"e_1_3_6_31_1","unstructured":"Kristinsson KG Erlendsd\u00f3ttir H Quirk S et al. Effect of pneumococcal vaccination on invasive pneumococcal disease in Iceland 2009\u20132015. Poster session presented at: 26th European Congress of Clinical Microbiology and Infectious Diseases; 2016 Apr 9\u201312; Amsterdam The Netherlands."},{"key":"e_1_3_6_32_1","volume-title":"Pneumococcal conjugate vaccine impact study (PCVIS) [internet]","author":"KEMRI Wellcome Trust","year":"2017","unstructured":"KEMRI Wellcome Trust. Pneumococcal conjugate vaccine impact study (PCVIS) [internet]. Kenya: KWTRP; 2017 [cited 2017 Nov 29]. Available from: http:\/\/kemri-wellcome.org\/programme\/pcvis-2\/"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177746"},{"key":"e_1_3_6_34_1","doi-asserted-by":"crossref","unstructured":"Massora S Mucavele H Lessa F et al. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease among children in Mozambique 2008\u20132016. 11th International Symposium on Pneumococci and Pneumococcal Diseases 2018 Apr 15\u201319; Melbourne Australia.","DOI":"10.26226\/morressier.5731f0d2d462b802923800f3"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.028"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.005"},{"key":"e_1_3_6_37_1","volume-title":"Public health surveillance information for New Zealand public health action - invasive pneumococcal disease reports [internet]","author":"Institute of Environmental Science & Research Limited","year":"2014","unstructured":"Institute of Environmental Science & Research Limited. Public health surveillance information for New Zealand public health action - invasive pneumococcal disease reports [internet]. New Zealand: Ministry of Health; 2014 [cited 2017 Nov 29]. Available from: https:\/\/surv.esr.cri.nz\/surveillance\/IPD.php"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2111.140780"},{"key":"e_1_3_6_39_1","volume-title":"Pneumokokken [internet]","author":"Netherlands Reference Laboratory for Bacterial Meningitis (AMC\/RIVM)","year":"2017","unstructured":"Netherlands Reference Laboratory for Bacterial Meningitis (AMC\/RIVM). Pneumokokken [internet]. Amsterdam: RIVM; 2017 [cited 2017 Nov 29]. Available from: http:\/\/www.rivm.nl\/Onderwerpen\/P\/Pneumokokken"},{"key":"e_1_3_6_40_1","unstructured":"Knol MJ Van der Ende A Sanders L et al. Vaccine effectiveness of 10-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: indirect cohort design. 10th International Symposium on Pneumococci and Pneumococcal Diseases; 2016 Jun 26\u201330; Glasgow UK."},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix685"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy316"},{"key":"e_1_3_6_43_1","volume-title":"GSK clinical study register: study numbers 113994, 116485 [internet]","year":"2017","unstructured":"GSK clinical study register: study numbers 113994, 116485 [internet]. UK: GSK;2017 [cited 2017 Nov 29]. Available from: https:\/\/www.gsk-clinicalstudyregister.com\/files2\/529cf371-82b1-40c4-9bed-2e116b36e6ac and https:\/\/www.gsk-clinicalstudyregister.com\/files2\/116485%20-%20Clinical-Study-Result-Summary.pdf"},{"key":"e_1_3_6_44_1","doi-asserted-by":"crossref","unstructured":"Odutola A Ota MC Antonio M et al. Immunogenicity and safety of an investigational protein-based pneumococcal vaccine in infants following 3+0 and 2+1 vaccination schedules: a phase II randomized trial in the Gambia. 10th International Symposium on Pneumococci & Pneumococcal Diseases; 2016 Jun 26\u201330; Glasgow UK.","DOI":"10.26226\/morressier.5731f0d6d462b8029237fe80"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1086\/593339"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1086\/528996"},{"key":"e_1_3_6_47_1","volume-title":"Synflorix, INN-Pneumococcal polysaccharide conjugate vaccine (adsorbed) [internet]","year":"2017","unstructured":"Synflorix, INN-Pneumococcal polysaccharide conjugate vaccine (adsorbed) [internet]. UK: European Medicines Agency; [cited 2017 Nov 29]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000973\/WC500054346.pdf"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70139-0"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-0458"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.13580"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.010"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200209000-00005"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71876-6"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035060"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819637af"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000232706.35674.2f"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02037-08"},{"key":"e_1_3_6_58_1","unstructured":"Kilpi T Palmu AA Puumalainen T et al. Effectiveness of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against hospital-diagnosed pneumonia in infants - FinIP trial. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; 2013 May 28\u2013Jun 1; Milan Italy."},{"key":"e_1_3_6_59_1","unstructured":"Kilpi T Jokinen J Puumalainen T et al. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against radiologically confirmed pneumonia. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014 Sep 5\u20139; Washington DC."},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1904.121198"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153141"},{"key":"e_1_3_6_62_1","first-page":"168","article-title":"Incidence of admissions due to pneumonia in children under 24 months old before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the National Immunization Program of Chile","volume":"86","author":"Fern\u00e1ndez VJP","year":"2015","unstructured":"Fern\u00e1ndez VJP, Goecke HC, von Borries C, et al. Incidence of admissions due to pneumonia in children under 24 months old before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the National Immunization Program of Chile. Rev Chil Pediatr. 2015;86:168\u2013172. Spanish.","journal-title":"Rev Chil Pediatr"},{"key":"e_1_3_6_63_1","unstructured":"Minamisava R Sgambatti S Morais-Neto OL et al. Impact of PCV10 introduction on pneumonia mortality rates in Brazil: a time series analysis. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India."},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172690"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.06.042"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.12.007"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000899"},{"key":"e_1_3_6_68_1","unstructured":"Silaba M Ooko M Bottomley C et al. The impact of 10-valent pneumococcal conjugate vaccine (PCV10) on the incidence of radiologically-confirmed pneumonia and on pneumonia hospitalizations among children in Kilifi Kenya. 10th International Symposium on Pneumococci and Pneumococcal Diseases; 2016 Jun 26\u201330; Glasgow UK."},{"key":"e_1_3_6_69_1","doi-asserted-by":"crossref","unstructured":"Verani J Bigogo G Muema S et al. Pneumonia-related mortality among children in an urban slum in Nairobi Kenya following 10-valent pneumococcal conjugate vaccine introduction. 10th International Symposium on Pneumococci and Pneumococcal Diseases; 2016 Jun 26\u201330; Glasgow UK.","DOI":"10.26226\/morressier.5731f0d7d462b8029238038c"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184204"},{"key":"e_1_3_6_71_1","unstructured":"Mucavele H Massora S Lessa F et al. Impact of 10-valent pneumococcal conjugate vaccine on radiologically confirmed pneumonia among children in Mozambique 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15\u201319; Melbourne Australia."},{"key":"e_1_3_6_72_1","unstructured":"Zhou Z Deceuninck G Boucher F et al. Impact of two pneumococcal conjugate vaccines on hospitalizations for lower-tract respiratory infections (LRTI) in Quebec Canada. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India."},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112211"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1287640"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S39637"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70338-4"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000857"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200301000-00006"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000133049.30299.5d"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68304-9"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001810"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001654"},{"key":"e_1_3_6_83_1","unstructured":"Talarico C Feng Y Medin E et al. Impact of pneumococcal conjugate vaccines (PCVs) on otitis media incidence in Swedish children. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15\u201319; Melbourne Australia."},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy233"},{"key":"e_1_3_6_85_1","unstructured":"Ey\u00feorsson ES Sigurdsson S Hrafnkelsson B et al. Pneumococcal vaccination in Iceland: PHiD-CV10 effectiveness against AOM associated antimicrobial prescriptions in children under three years of age. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15\u201319; Melbourne Australia."},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001722"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179222"},{"key":"e_1_3_6_88_1","unstructured":"De Wals P Fratu R Defay F et al. Frequency of visits for otitis media in Quebec: face-to-nape comparison of children exposed to PCV-7 or PHiD-CV. 31st Meeting of the European Society for Paediatric Infectious Diseases; 2013 May 28\u2013Jun 1; Milan Italy."},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)00938-7"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103293"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.53"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000083"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08717-0"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098128"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.09.027"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.020"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70224-4"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.019"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-318"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001705"},{"key":"e_1_3_6_101_1","unstructured":"Hammitt LL Akech DO Morpeth SC et al. Population impact of 10-valent pneumococcal conjugate vaccine (PCV) on nasopharyngeal carriage of Streptococcus pneumoniae in Kilifi Kenya. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15\u201319; Melbourne Australia."},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000084"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.03.030"},{"key":"e_1_3_6_104_1","doi-asserted-by":"crossref","unstructured":"Palmu AA Jokinen J Ruokokoski E et al. Indirect impact of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV10) on suspected non-confirmed invasive pneumococcal disease (IPD) in cluster-randomized trial. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India.","DOI":"10.1016\/S2213-2600(14)70139-0"},{"key":"e_1_3_6_105_1","unstructured":"Kilpi T Palmu AA Ruokokoski E et al. Indirect impact of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV10) on invasive pneumococcal disease (IPD) in a clinical trial. 8th World Congress of the World Society for Pediatric Infectious Diseases; 2013 Nov 19\u201322; Cape Town South Africa."},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.14335"},{"key":"e_1_3_6_107_1","unstructured":"Nuorti JP Rinta-Kokko H Toropainen M et al. Invasive pneumococcal disease among adults after routine infant conjugate vaccination in Finland - implications for vaccination policy. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India."},{"key":"e_1_3_6_108_1","unstructured":"Caier\u00e3o J Cunha G d\u2019Azevedo PA et al. Distribution of pneumococcal serotypes after introduction of 10-valent conjugate vaccine: a study involving adults with invasive disease Porto Alegre Brazil. 8th International Symposium on Pneumococci and Pneumococcal Diseases; 2012 Mar 11\u201315; Igua\u00e7u Falls Brazil."},{"key":"e_1_3_6_109_1","unstructured":"Azevedo J Soares Santos M Santos Galv\u00e3o V et al. The burden of invasive pneumococcal disease among older patients in the era of conjugate vaccine. 9th International Symposium on Pneumococci & Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India."},{"key":"e_1_3_6_110_1","unstructured":"Lobo PR Azevedo J Silva E et al. Epidemiology of pneumococcal meningitis in the metropolitan region of Salvador Brazil before and after the introduction of PCV10. Poster session presented at: 9th International Symposium on Pneumococci and Pneumococcal Diseases; 2014 Mar 9\u201313; Hyderabad India."},{"key":"e_1_3_6_111_1","unstructured":"Palmu A Jokinen J Puumalainen T et al. Indirect impact of pneumococcal Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV10) on hospital-diagnosed pneumonia in cluster-randomized trial. 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases; 2015 May 12\u201316; Leipzig Germany."},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210440"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.049"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036226"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70075-4"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.019"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.088"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001517"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62225-8"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2301.160897"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194823"},{"key":"e_1_3_6_122_1","unstructured":"Hj\u00e1lmarsd\u00f3ttir M\u00c1 Quirk SJ Sveinsd\u00f3ttir H et al. Pneumococcal vaccination in Iceland: the effect on antimicrobial susceptibility and serotype distribution. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15\u201319;Melbourne Australia."},{"key":"e_1_3_6_123_1","unstructured":"Chauque A Lessa F Moiane B et al. Declines in antimicrobial resistant (AMR)-Streptococcus pneumoniae after introduction of 10-valent pneumococcal conjugate vaccine (PCV10) in Mozambique. 11th International Symposium on Pneumococci and Pneumococcal Diseases; 2018 Apr 15\u201319; Melbourne Australia."},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-15"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0062-1"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/591580"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1362339"},{"key":"e_1_3_6_128_1","volume-title":"Pneumococcal conjugate vaccine (PCV) product assessment. April 2017 [internet]","author":"Cohen O","year":"2017","unstructured":"Cohen O, Knoll M, O\u2019Brien K, et al. Pneumococcal conjugate vaccine (PCV) product assessment. April 2017 [internet]. Baltimore: IVAC; 2017 [cited 2017 Nov 29]. Available from: https:\/\/www.jhsph.edu\/research\/centers-and-institutes\/ivac\/resources\/pcv-product-assessment-april-25-2017.pdf."}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2018.1516551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:03:26Z","timestamp":1772715806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2018.1516551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,2]]},"references-count":126,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,2]]}},"alternative-id":["10.1080\/14760584.2018.1516551"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2018.1516551","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}